Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteers

• ClinicalTrials.gov Identifier: NCT03858725
• Recruitment Status: Completed
• First Posted: March 1, 2019
• Last Update Posted: January 30, 2020
• Sponsor: Chong Kun Dang Pharmaceutical
• Information provided by (Responsible Party): Chong Kun Dang Pharmaceutical

Study Description

Brief Summary:

This study is a randomized, open-label, fasted, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-374 5 mg in healthy volunteers.

Condition or disease	Intervention/treatment	Phase
Rheumatoid Arthritis	Drug: D569 Tab.; Drug: CKD-374 5mg Tab.	Phase 1

Detailed Description:

To healthy subjects of thirty-six (36), following treatments are administered dosing in each period and wash-out period is a minimum of 7 days.

Reference drug: D569 Tab. / Test drug: CKD-374 5mg Tab. Pharmacokinetic blood samples are collected up to 12hrs. The pharmacokinetic characteristics and safety are assessed

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 36 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Randomized, Open-label, Fasted, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteer
• Actual Study Start Date: February 26, 2019
• Actual Primary Completion Date: April 5, 2019
• Actual Study Completion Date: May 8, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: D569/CKD-374 5mg; Period 1: D569 Tab. 1T; Period 2: CKD-374 5mg Tab. 1T	Drug: D569 Tab.; D569 Tab. 1T single oral administration under fasting condition; Drug: CKD-374 5mg Tab.; CKD-374(Tofacitinib) 5mg Tab. 1T single oral administration under fasting condition
Experimental: CKD-374 5mg/D569; Period 1: CKD-374 5mg Tab. 1T; Period 2: D569 Tab. 1T	Drug: D569 Tab.; D569 Tab. 1T single oral administration under fasting condition; Drug: CKD-374 5mg Tab.; CKD-374(Tofacitinib) 5mg Tab. 1T single oral administration under fasting condition

Outcome Measures

Primary Outcome Measures :

1. AUCt of CKD-374 and D569 [ Time Frame: [Time Frame: Pre-dose (0 hour), post-dose 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours] ]
   Area under the CKD-374/ D569 concentration in blood-time curve from zero to final
2. Cmax of CKD-374 and D569 [ Time Frame: [Time Frame: Pre-dose (0 hour), post-dose 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours] ]
   The maximum CKD-374/ D569 concentration in blood sampling time t

Eligibility Criteria

• Ages Eligible for Study: 19 Years to 54 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Healthy subject older than 19 years and less than 55 years at the screening

2. Individuals who had 17.5 kg/m2 ≤ Body Mass Index(BMI) < 30.5kg/m2 and a total body weight ≥ 55 kg

   * BMI = Weight(kg)/ Height(m)2

3. Individuals without congenital/chronic diseases and without abnormal symptoms or diagnosis based on a medical examination within the last 3 years
4. Individuals who were deemed to be appropriate as study subjects in accordance with the screening results (laboratory tests, vital signs, ECG, chest X-ray etc.)
5. Individuals who signed an informed consent form approved by the IRB of Chonbuk National University Hospital and decided to participate in the study after being fully informed of the study prior to participation, including the objective, content and characteristics of the investigational drug
6. Individuals with the ability and willingness to participate during the study period

Exclusion Criteria:

1. Individuals with a medical evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurologic or immune disease (excluding simple dental history such as dental calculus, impacted tooth, wisdom tooth, etc.)
2. Individuals with a medical history of gastrointestinal disease (e.g., gullet disease including esophageal achalasia, esophagostenosis, or Crohn's disease) or operations (excluding simple appendectomy, herniotomy, or tooth extraction surgery) that may affect drug absorption
3. Individuals with the following laboratory test results: ALT or AST > 2x the upper limit of the normal range
4. A history of regular alcohol consumption exceeding 210 g/week within the 6 months prior to screening (1 drink (250 mL) of beer (5%) = 10 g; 1 drink (50 mL) of hard liquor (20%) = 8 g; 1 drink (125 mL) of wine (12%) = 12 g)
5. Individuals who smoked more than 20 cigarettes per day within 6 months prior to screening
6. Individuals who had been administered investigational product(s) of other clinical study or bioequivalence study within the 3 months prior to the first dose of this study

7. Individuals with the following vital signs results at screening

   *Individuals who had sitting blood pressure ≥90 mmHg or <140 mmHg (systolic) or ≥90 mmHg or <60 mmHg (diastolic)

8. Individuals with a medical history of significant alcohol abuse or drug abuse within one year prior to the screening
9. Individuals who had taken any drug(s) known as a strong inducer(s) or inhibitor(s) of drug-metabolizing enzymes within 30 days prior to the first dose of investigational product(s)
10. Individuals who had taken prescription or nonprescription drugs within the 10 days prior to the first dose of investigational product(s)
11. Individuals who donated whole blood within the 2 months, or blood components within 1 month prior to the first dose of the investigational product(s)
12. Individuals with severe acute/chronic medical or psychiatric conditions that may increase the risk associated with study participation or investigational product(s) administration, or may interfere with the interpretation of study results
13. Individuals with hypersensitivity to ingredients used in the investigational product(s)
14. Patients with serious infection (e.g., Sepsis) or active infection including localized infection or history of interstitial pneumonia
15. Patients with active tuberculosis or history of tuberculosis
16. Patients with hepatopathy
17. Patients with an absolute neutrophil count (ANC) less than 1000 /ul
18. Patients with an absolute lymphocyte count (ALC) less than 500 /ul
19. Patients who have hemoglobin levels less than 9 g/dL
20. Women who are pregnant or may be pregnant
21. Patients with hereditary diseases of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption etc.
22. Patients with nephropathy (eGFR<60 ml/min/1.73 m2)
23. Individuals who were deemed to be inappropriate to participate in the study by the investigator

Contacts and Locations

Locations

Korea, Republic of

Chonbuk National University Hospital

Jeonju, Korea, Republic of

Sponsors and Collaborators

Chong Kun Dang Pharmaceutical

Investigators

• Principal Investigator: Kyung-Ho Jang; Chonbuk National University Hospital

More Information

• Responsible Party: Chong Kun Dang Pharmaceutical
• ClinicalTrials.gov Identifier: NCT03858725
• Other Study ID Numbers: 190BE18031
• First Posted: March 1, 2019
• Last Update Posted: January 30, 2020
• Last Verified: January 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Arthritis; Arthritis, Rheumatoid; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases